Department of Transfusion Medicine, Infectious Diseases and Immunogenetics Section (IDIS) Clinical Center and Center for Human Immunology, issue.7 10 ,
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010. ,
DOI : 10.1056/NEJMoa1003466
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-828, 2010. ,
DOI : 10.1056/NEJMoa1002011
Measuring the Results of Science Investments, Science, vol.331, issue.6018, pp.678-80, 2011. ,
DOI : 10.1126/science.1201865
The gene expression signatures of melanoma progression, Proceedings of the National Academy of Sciences, vol.102, issue.17, pp.6092-6099, 2005. ,
DOI : 10.1073/pnas.0501564102
A multi-marker assay to distinguish malignant melanomas from benign nevi, Proceedings of the National Academy of Sciences, vol.106, issue.15, pp.6268-72, 2009. ,
DOI : 10.1073/pnas.0901185106
Prognostic Significance of Nuclear Receptor Coactivator-3 Overexpression in Primary Cutaneous Melanoma, Journal of Clinical Oncology, vol.24, issue.28, pp.4565-4574, 2006. ,
DOI : 10.1200/JCO.2006.07.3833
A Multimarker Prognostic Assay for Primary Cutaneous Melanoma, Clinical Cancer Research, vol.15, issue.22, pp.6987-92, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1777
Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor???Based Antitumor Vaccine, Journal of Clinical Oncology, vol.25, issue.18, pp.2546-53, 2007. ,
DOI : 10.1200/JCO.2006.08.5829
Down-Regulation of the Interferon Signaling Pathway in T Lymphocytes from Patients with Metastatic Melanoma, PLoS Medicine, vol.19, issue.5, p.176, 2007. ,
DOI : 10.1371/journal.pmed.0040176.st002
Impaired interferon signaling is a common immune defect in human cancer, Proceedings of the National Academy of Sciences, vol.106, issue.22, pp.9010-9015, 2009. ,
DOI : 10.1073/pnas.0901329106
Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694, Journal of Clinical Oncology, vol.27, issue.1, pp.38-44, 2009. ,
DOI : 10.1200/JCO.2008.17.1777
T cell defined tumor antigens, Current Opinion in Immunology, vol.9, issue.5, pp.684-93, 1997. ,
DOI : 10.1016/S0952-7915(97)80050-7
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report, European Journal of Cancer, vol.39, issue.1, pp.70-77, 2003. ,
DOI : 10.1016/S0959-8049(02)00479-3
Immunization with the recombinant MAGE-A3 protein combined with Adjuvant Systems AS02B or AS15 in patients with metastatic melanoma: final results of a Phase II study of the EORTC Melanoma Group, pp.0-0001, 2009. ,
MAGE-A3 Antigen-Specific Cancer Immunotherapy (ASCI) clinical activity in metastatic melanoma is associated with predictive biomarkers present in the tumor prior to immunization [abstract]. Canadian Melanoma Conference, 2010. ,
Phase II randomized study of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II Non- Small Cell Lung Cancer (NSCLC): 44 month follow-up, humoral and cellular immune response data, p.148, 2008. ,
Abstract A37: Identification of a gene expression signature predictive of clinical activity following MAGE-A3 ASCI treatment, Molecular Cancer Therapeutics, vol.8, issue.Supplement 1, p.1, 2009. ,
DOI : 10.1158/1535-7163.TARG-09-A37
A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma [abstract], Proc Am Soc Clin Oncol, vol.27, p.18, 2009. ,
Melanoma: A model for testing new agents in combination therapies, Journal of Translational Medicine, vol.8, issue.1, p.38, 2010. ,
DOI : 10.1186/1479-5876-8-38
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, New England Journal of Medicine, vol.353, issue.25, pp.2654-66, 2005. ,
DOI : 10.1056/NEJMoa051424
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, issue.5795, pp.1960-1964, 2006. ,
DOI : 10.1126/science.1129139
Histopathologicalbased prognostic factors of colorectal cancers are associated with the state of the local immune reaction, J Clin Oncol ,
The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective, Cancer Research, vol.67, issue.5, pp.1883-1889, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-4806
Natural immunity to cancer in humans, Current Opinion in Immunology, vol.22, issue.2, pp.215-237, 2010. ,
DOI : 10.1016/j.coi.2010.02.006
Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer, Gastroenterology, vol.138, issue.4, pp.1429-1469, 2010. ,
DOI : 10.1053/j.gastro.2009.10.057
In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5944-51, 2009. ,
DOI : 10.1200/JCO.2008.19.6147
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma, Cancer, vol.49, issue.7, pp.1303-1313, 1996. ,
DOI : 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
Immune infiltration in human tumors: a prognostic factor that should not be ignored, Oncogene, vol.173, issue.8, pp.1093-102, 2010. ,
DOI : 10.1038/nrc1586
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010", Journal of Translational Medicine, vol.9, issue.1, p.32, 2010. ,
DOI : 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
URL : https://hal.archives-ouvertes.fr/inserm-00834025